John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal residual disease (MRD) is a valid endpoint when measuring treatment efficacy in chronic lymphocytic leukemia (CLL).
Whether MRD is a Valid Endpoint When Measuring Treatment Efficacy in CLL
